Oncology Peer Review On-The-Go: Experts Share Multidisciplinary Takeaways From 2022 SABCS

Podcast

Judy C. Boughey, MD; Robert Mutter, MD; and Siddhartha Yadav, MD, MBBS, of Mayo Clinic spoke with CancerNetwork® multidisciplinary findings presented at the 2022 San Antonio Breast Cancer Symposium, ranging from surgery to radiotherapy to biomarker research.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with several multidisciplinary oncology experts from the Mayo Clinic in Rochester, Minnesota about their respective key takeaways from the presentations on developments in the breast cancer space, including surgery, radiotherapy, and biomarker research.

Judy C. Boughey, MD, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery, discussed her research on the impact of breast conservation therapy on local recurrence rates in multiple ipsilateral breast cancer in the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243).

Robert Mutter, MD, an associate professor of the Department of Radiation Oncology, spoke about his work on a randomized phase 2 trial assessing the use of conventional vs hypofractionated proton radiotherapy following a mastectomy among patients with breast cancer.

Siddhartha Yadav, MD, MBBS, a medical oncologist and assistant professor of Medicine and Oncology, highlighted data from the population-based CARRIERS study, assessing germline pathogenic variants and other factors as risks for contralateral breast cancer.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content